Aspen is in a closed period from 1st July 2025 until the publication of the annual results on the JSE SENS platform on the 3rd September 2025.
The true heroes of our Mandela Day campaign are our employees who continue to volunteer
The true heroes of our Mandela Day campaign are our employees who continue to volunteer to make a difference through their acts of selfless generosity, humility and care for those in need.
Aspen Pharmacare Holdings has reported positive Group interim financial results for the six months ended 31 December 2024.
Aspen has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro®, a therapeutic option available to physicians for the treatment of Type II diabetes.
Aspen and SEMDSA earlier today raised awareness around the alarming rise of non-communicable diseases, particularly diabetes, in recognition of World Diabetes Day.
Aspen’s Stephen Saad and Sean Capazorio will take part in Investec’s CEO conference in London from 14 to 15 November 2024.
Aspen has contributed towards the funding of a new mobile cancer screening clinic for rural and peri-urban disadvantaged communities.
JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid Group financial results for the year ended 30 June 2024.
Durban – JSE Limited listed Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded pharmaceutical company, is celebrating its 14th consecutive year of Group-wide
Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912
Medical Careline (South Africa) 0800 118 088
ASPEN PHARMACARE HOLDINGS LTD:
Switchboard: +27 31 580-8600
Aspen Place
9 Rydall Vale Park
Douglas Saunders Drive
La Lucia Ridge
South Africa
Shauneen Beukes
Group Communications Consultant
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com
